SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Suppliers

Read more breaking news

 

 
News in brief

GSK not A-OK with Ribena, Lucozade? Strategic review begins…

By Ben Bouckley+

07-Feb-2013
Last updated on 07-Feb-2013 at 15:07 GMT2013-02-07T15:07:15Z

GSK not A-OK with Ribena, Lucozade? Strategic review begins…

GlaxoSmithKline (GSK) has launched a strategic review of its Lucozade and Ribena brands, hinting that the western-facing brands do not fit its increased focus on emerging markets such as China and India.

Announcing GSK’s Q4 2012 results yesterday, CEO Andrew Witty said that Glaxo was increasing its focus on a core portfolio of healthcare brands and in emerging markets, “where we are seeing very positive consumption trends and benefit from sales and distribution synergies with pharmaceuticals".

GSK reported a 2012 turnover of £25.431bn or $34.247bn (-3%) and an operating profit of £7.392bn (-5%); Q4 turnover fell 3% to £6.802bn but quarterly operating profit rose 3% to £1.94bn. (N.B. We are not reporting these figures on a constant currency basis.)

Discussing the ‘excellent progress’ of GSK’s Consumer Healthcare business, Witty noted divisional sales up 5% for FY 2012, but mentioned “clear adverse impact” from European sales (-7%).

Review looks to grow 'iconic brands'

“Investments to maximize returns in these markets continue. Last year, we opened a new innovation center in China, and most recently, we increased our shareholding in our Indian subsidiary,” he said.

In line with this strategic focus, Witty said that GSK had decided to begin a review evaluating all strategic options for its Lucozade and Ribena drinks brands, which fall within its Consumer Healthcare business, and “are primarily marketed in established western markets”.

“These brands are iconic and the review will look at the best ways to ensure their continued growth,” Witty added.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars